Evidence map›Paper›PMID 33815290›Full record

ArticleFrontiers in endocrinology2021

Safety of Ovaleap® (Follitropin Alfa) in Infertile Women Undergoing Superovulation for Assisted Reproductive Technologies: A Multinational Comparative, Prospective Cohort Study.

Sigal Kaplan, Rachel Levy-Toledano, Miranda Davies, Debabrata Roy, Colin M Howles, Amir Lass

Open access · goldAbstract readComparative StudyMulticenter Study
In one paragraph

Article in Frontiers in endocrinology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Sigal KaplanGlobal Patient Safety & Pharmacovigilance, Teva Pharmaceutical Industries Ltd., Netanya, Israel.
Rachel Levy-ToledanoRLT Media Consulting, Boulogne Billancourt, France.
Miranda DaviesDrug Safety Research Unit, Southampton, United Kingdom.
Debabrata RoyDrug Safety Research Unit, Southampton, United Kingdom.
Colin M HowlesMedical Department, Theramex Ltd., London, United Kingdom.
Amir LassMedical Department, Theramex Ltd., London, United Kingdom.
Drug Safety Research Unit · GBTeva Pharmaceuticals (Israel) · ILUniversity of Portsmouth · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Ovaleap Methods: Safety of Ovaleap Results: A total of 408 women who were administered Ovaleap Conclusions: Findings from the SOFIA study indicate that the incidence proportions of OHSS and OHSS severity, as well as pregnancy and live birth rates, are similar between Ovaleap

Indexed as

Reproductive Techniques, AssistedSuperovulationAdultFemaleFertilization in VitroFollicle Stimulating HormoneFollicle Stimulating Hormone, HumanHumansIncidenceInfertility, FemaleInternational CooperationMiddle AgedMulticenter Studies as TopicOvarian Hyperstimulation SyndromeOvulation InductionProspective StudiesFollicle Stimulating HormoneFollicle Stimulating Hormone, Humanfollitropin alfaRecombinant Proteinsfollitropin alfaGonal-f®live birth rateOvaleap®ovarian hyperstimulation syndromepregnancy outcomepregnancy ratesafety

Identifiers

PMID33815290
PMCPMC8010350
OpenAlexW3136761682

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.